.- Jan Steyaert , scientific director of the VIB-VUB Center for Structural Biology , Vlaams Instituut recognizes the combination of Steyaert’s fundamental research and his ability to apply the research to the development Read more at the source #DrGPCR #GPCR #IndustryNews

CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases , inflammatory disorders and cancer, today announced that the companies have entered into a definitive Read more at the source #DrGPCR #GPCR #IndustryNews

SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financial results for the Q1 2023 and continue to evaluate the path forward for dipraglurant in a number of interesting disease areas in parallel to discussions with potential strategic partners.”" Read more at the source #DrGPCR #GPCR #IndustryNews

(Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results Read more at the source #DrGPCR #GPCR #IndustryNews

lifescience #immunology #antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies #drugdiscovery research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals #oncology #healthcare #drugdevelopment " Read more at the source #DrGPCR #GPCR #IndustryNews

Jonah Comstock delves into what makes this team-up tick. Cancer Research UK , a charity dedicated to funding lifesaving oncology research, spent £388 million Much of that funding is distributed to support third party research, but the group also does its own the necessary tools to drive it forward." Read more at the source #DrGPCR #GPCR #IndustryNews

"Dear Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases , such as cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or Read more at the source #DrGPCR #GPCR #IndustryNews

However, these drugs show adverse effects, including increased blood pressure in mirabegron patients. Hence, new β3 -AR agonists are needed as starting points for drug development. Previous pharmacophore modeling studies of the β3 -AR did not involve experimental in vitro validation A dataset consisting of β3 -AR agonists was prepared to build and validate the pharmacophore models. Read more at the source #DrGPCR #GPCR #IndustryNews

Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded Read more at the source #DrGPCR #GPCR #IndustryNews

are well-known regulators of the development and functions of numerous tissues. ACKR3 has been described as an atypical "biased" receptor because it does not appear to signal through of residues in the transmembrane domains of ACKR3. these small molecules and ACKR3 was defined. Read more at the source #DrGPCR #GPCR #IndustryNews

The mambaquaretin-1 (MQ1) peptide identified from the Dendroaspis angusticeps venom is the most selective MQs form a new subgroup in the Kunitz family, close to the V2R non-active dendrotoxins and to two V2R-active We finally determined that eight positions, part of these two loops, interact with the V2R. MQ1-K39A represents the first step in the improvement of the MQ1 design from a medicinal perspective. Read more at the source #DrGPCR #GPCR #IndustryNews

Read more at the source #DrGPCR #GPCR #IndustryNews

) ligands and analogues for their pharmacologic activities and potential therapeutic utility toward diseases Divergence, however, in the amino acid sequences of rodent and human PTH receptors (rat and mouse PTH1Rs are 91% identical to the human PTH1R) can lead to differences in receptor-binding and signaling potencies Expression is directed by the endogenous mouse promoter and hence occurs in all biologically relevant Read more at the source #DrGPCR #GPCR #IndustryNews

The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead Read more at the source #DrGPCR #GPCR #IndustryNews

July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON-- Tectonic Therapeutic , Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Read more at the source #DrGPCR #GPCR #IndustryNews

Read more at the source #DrGPCR #GPCR #IndustryNews

Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates to enter clinical trials, the first AI-driven precision medicine platform clinically validated to guide We’re excited about delivering the next ten years of Exscientia and advancing AI to design better drugs #artificialintelligence #drugdesign #drugdiscovery" Read more at the source #DrGPCR #GPCR #IndustryNews

When I came this morning to work this is how I found my desk. So very grateful to the great hard working team we have and all the great achievements we have done together forward for more 🎊 #team #grateful #biotech #work #birthdaycelebration" Read more at the source #DrGPCR

ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR #IndustryNews

Read more at the source #DrGPCR #GPCR #IndustryNews

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease , congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study." Read more at the source #DrGPCR #GPCR #IndustryNews

do better. Dr. course by Dr. Dr. GPCR Volunteers Join our dynamic team as a volunteer! in Cardiovascular Health and its Therapeutic Implications The perspective of cAMP/cGMP signaling and cyclic

Read more at the source #DrGPCR #GPCR #IndustryNews

venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced four appointments Dr. Michel Bouvier , Dr. Luisa Salter-Cid , Dr. Omar Nadeem and Dr. Jon Wigginton will provide scientific expertise to support the company’s research and clinical development Read more at the source #DrGPCR #GPCR #IndustryNews

signaling events, including the modulation of cyclic adenosine monophosphate (cAMP), calcium mobilization GPCR activity, particularly in drug discovery endeavors [2]. of drug kinetics—a critical aspect in drug development [14]. G protein detector. and a G protein detector tagged with an Nluc donor.

Read more at the source #DrGPCR #GPCR #IndustryNews

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first Read more at the source #DrGPCR #GPCR #IndustryNews

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company Read more at the source #DrGPCR #GPCR #IndustryNews